Biotech Startup Successfully Scales mRNA Manufacturing
How a small biotech company scaled mRNA vaccine production from lab to commercial scale.
1 min read2029 viewsPublished April 20, 2025
Biotech Startup Successfully Scales mRNA Manufacturing
Background
A small biotech company with a promising mRNA therapeutic needed to rapidly scale from research quantities to commercial manufacturing.
The Challenge
- Lab-scale process producing only milligrams
- Need to reach kilogram-scale within 18 months
- Limited internal manufacturing expertise
The Solution
CDMO Selection Process
The company used a structured evaluation to select a CDMO partner with:
- Existing mRNA manufacturing capabilities
- Regulatory track record with novel modalities
- Flexible capacity and scale-up expertise
Results
- Achieved commercial scale in 14 months
- 95% batch success rate at scale
- Regulatory approval in multiple markets
- Cost reduction of 60% vs. in-house projections
Key Learnings
- Early CDMO engagement accelerates timelines
- Joint team structure improves communication
- Flexible contract terms enable rapid scaling
Was this article helpful?
Sign in to provide feedback